| Item 2.02. | Results of Operations and Financial Condition. |
On January 8, 2024, Veracyte, Inc., a Delaware corporation (“Veracyte”), issued a press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Press Release”) that, among other things, announced certain preliminary financial and operating results for the fourth quarter and year ended December 31, 2023, including that Veracyte expects to report that it generated total revenue of between $95.0 million and $96.0 million, and that its total test volume was approximately 34,000 tests, in each case for the fourth quarter of 2023. Veracyte also expects to report total revenue of between $358.0 million and $359.0 million and total test volume of approximately 127,000 tests for the full year ended December 31, 2023. In addition, Veracyte expects to report that cash, cash equivalents and short-term investments were more than $215.0 million as of December 31, 2023.
Veracyte’s audited financial statements for the year ended December 31, 2023 are not yet available. Accordingly, Veracyte’s preliminary revenue and cash information in the Press Release and described herein are estimates and subject to the completion of Veracyte’s financial closing procedures and any adjustments that may result from the completion of the audit of Veracyte’s financial statements. The preliminary revenue and cash information in the Press Release and described herein may differ materially from the actual results that will be reflected in Veracyte’s audited financial statements when they are completed and publicly disclosed.
In the Press Release, also on January 8, 2024, Veracyte reported the execution of an agreement and plan of merger with C2i Genomics, Inc. (“C2i”). The Press Release is incorporated herein by reference. On January 8, 2024, Veracyte posted supplemental investor materials on the Investors Relations section of its website, available at https://investor.veracyte.com/.
The information furnished with this report, including the information included in Items 2.02 and 7.01, as well as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Forward-Looking Statements
This Current Report on Form 8-K, including the Press Release, contains “forward-looking” statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act which involve risks and uncertainties. These forward-looking statements include, but are not limited to, statements related to Veracyte’s plans, objectives and expectations (financial and otherwise), including with respect to 2023 and 2024 financial and operating results; Veracyte’s anticipated acquisition of C2i; statements regarding the expected benefits of the acquisition, including but not limited to Veracyte’s expectation that adding whole-genome minimal residual disease capabilities to its unique diagnostics platform will position Veracyte to serve physicians and their patients further along the care continuum, that Veracyte believes this C2i’s technology will enable it to measure a tumor’s progression as it evolves from early diagnosis through patient treatment and follow-ups; and Veracyte’s intentions with respect to its tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by the use of terminology such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from Veracyte’s predictions, and include, but are not limited to: Veracyte’s ability to launch, commercialize and receive reimbursement for its products; the ability of the parties to complete the acquisition of C2i on a timely basis or at all, including the required satisfaction or waiver of the closing conditions; Veracyte’s and C2i’s ability to execute on its business strategies relating to the acquisition and realize expected benefits and synergies; the retention of certain of C2i’s employees and Veracyte’s ability to successfully integrate the C2i business; the risk of stockholder litigation in connection with the contemplated transaction; Veracyte’s ability to demonstrate the validity and utility of its genomic tests and biopharma and other offerings; Veracyte’s ability to continue executing on Veracyte’s business plan; Veracyte’s ability to continue to scale its global operations and enhance its internal control environment; the impact of the war in Ukraine on European economies and energy supply and other regional conflicts, as well as Veracyte’s facilities in France; the impact of foreign currency fluctuations, increasing interest rates, inflation, potential government shutdowns and turmoil in the global banking and finance system; and
